(Sharecast News) - Shares in Swiss healthcare company Roche surged to an eight-month high on Tuesday after results from a clinical trial of its giredestrant drug supported its potential as a new standard-of-care endocrine therapy for early-stage breast cancer.
Phase III results from the lidERA breast cancer study met their primary...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE